Inclusion Criteria:

          -  Participant must have histologically or radiographically confirmed hepatocellular
             cancer (HCC) that is advanced or metastatic and if archival tissue is available, have
             archival tissue submitted for PD-L1, PD-L2 testing

          -  Participants with measurable disease that has progressed are eligible if prior surgery
             or locoregional therapy occurred > 28 days prior to enrollment

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Karnofsky
             >= 60%)

          -  Child-Pugh class-A liver function

          -  Absolute neutrophil count (ANC) >= 1,500/ mcL

          -  Hemoglobin >= 8.5 g/dL

          -  Platelets >= 75,000/ mcL

          -  Total bilirubin =< 2.0 mg/dL

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 X ULN

          -  Serum Creatinine <= 1.5 upper limit of normal (ULN)or Creatinine clearance > 50
             mL/minute if serum creatinine is elevated above 1.5 X ULN

          -  Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
             criteria present

          -  Ability to swallow and retain oral medication

          -  Participants of child-bearing potential must agree to use adequate contraceptive
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study
             entry; should a woman become pregnant or suspect she is pregnant while she or her
             partner is participating in this study, she should inform her treating physician
             immediately

          -  Participant must understand the investigational nature of this study and sign an
             Independent Ethics Committee/Institutional Review Board approved written informed
             consent form prior to receiving any study related procedure

          -  Participants with past or ongoing hepatitis C virus (HCV) infection will be eligible
             for the study. The treated participants must have completed their treatment at least 1
             month prior to starting study intervention.

          -  Participants with controlled hepatitis B will be eligible as long as they meet the
             following criteria:

        Antiviral therapy for HBV must be given for at least 12 weeks and HBV viral load must be
        less than 100 IU/ml prior to first dose of study drug. Participants on active HBV therapy
        with viral loads under 100 IU/mL should stay on the same therapy throughout study treatment
        Participants who are anti-HBc , negative for Hepatitis B surface antigen (HBsAg) and
        negative or positive for anti-HBs, and who have an HBV viral load under 100 IU/mL , do not
        require HBV anti-viral prophylaxis

        Exclusion Criteria:

          -  One prior line of therapy that may include a PDL1 blocker allowed, no prior sorafenib
             or PD1 blocker allowed.

          -  Participants who have had radiotherapy or chemotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier

          -  Any evidence of bleeding diathesis (patients on therapeutic warfarin or heparin will
             be excluded)

          -  Participants with a history of variceal bleed within 6 months prior to enrollment

          -  Known human immunodeficiency virus (HIV)-positive participants (even if on combination
             retrovirals, participant will be excluded

          -  Participants with chronic autoimmune disease

          -  Participants with known brain metastases should be excluded from this clinical trial

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Has known history of, or any evidence of active, non-infectious pneumonitis

          -  Pregnant or nursing female participants

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the Investigator's opinion deems the participant an unsuitable
             candidate to receive study drug

          -  Received a live vaccine within 30 days prior to start of study treatment